Deutsche Bank downgrades AstraZeneca shares despite positive tozorakimab data

LONDON (AP) — Deutsche Bank issued a "sell" rating on AstraZeneca PLC shares on Wednesday, citing concerns over long-term revenue projections even as the pharmaceutical giant reported encouraging clinical results for its experimental lung disease drug, tozorakimab. The recommendation, released just before market close in London and during trading hours in New York, marked a sharp divergence between the scientific optimism surrounding the compound and the bank's financial outlook for the company.

The downgrade comes after AstraZeneca unveiled data suggesting tozorakimab shows significant promise in treating chronic obstructive pulmonary disease. The positive clinical readout had initially sparked investor interest across the London Stock Exchange and the NASDAQ, where the UK-based firm trades under the ticker AZN. However, Deutsche Bank analysts paired their favorable assessment of the drug's efficacy with a bearish verdict on the stock's valuation.

In its research note, the bank highlighted that while the tozorakimab data is robust, market consensus forecasts for the drug's peak sales in 2030 hover around $4 billion. Deutsche Bank analysts argued that this revenue potential does not justify current share prices, suggesting that the market has already priced in the positive outcomes or that the ceiling for commercial success is lower than investor expectations imply. The bank maintained its view that AstraZeneca's broader portfolio faces headwinds that outweigh the immediate benefits of a single successful candidate.

AstraZeneca shares experienced volatility following the announcement, dipping slightly before stabilizing as traders digested the mixed signals from the banking sector. The firm has not yet issued a public statement addressing Deutsche Bank's specific valuation concerns, though company executives have previously emphasized their confidence in the tozorakimab pipeline and its potential to capture a significant share of the global respiratory market.

The situation highlights a recurring tension in the biopharmaceutical sector, where strong clinical data does not always translate immediately into stock price appreciation if financial models suggest limited commercial upside. Analysts from other major institutions have yet to issue updated ratings following Deutsche Bank's move, leaving investors to weigh the drug's medical breakthrough against the bank's conservative sales estimates.

As trading continues, the focus remains on whether other Wall Street and City of London analysts will align with Deutsche Bank's cautious stance or if the positive clinical data will ultimately drive a re-rating of AstraZeneca's shares. The coming days will be critical in determining if the $4 billion sales forecast becomes a self-fulfilling prophecy or if market sentiment shifts to reflect the drug's broader therapeutic potential.